ZNF562

Summary

ZNF562 (zinc finger protein 562, HGNC:25950) is a protein-coding gene on chromosome 19p13.2, encoding Zinc finger protein 562 (Q6V9R5). May be involved in transcriptional regulation.

Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Predicted to be involved in regulation of DNA-templated transcription. Predicted to be located in nucleus.

Source: NCBI Gene 54811 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 66 total — 1 likely-pathogenic
• Phenotypes (HPO): 1
• MANE Select transcript: NM_001130031

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25950
Approved symbol	ZNF562
Name	zinc finger protein 562
Location	19p13.2
Locus type	gene with protein product
Status	Approved
Aliases	FLJ20079
Ensembl gene	ENSG00000171466
Ensembl biotype	protein_coding
Entrez	54811

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 14 protein_coding, 1 nonsense_mediated_decay

ENST00000293648, ENST00000453372, ENST00000585350, ENST00000585688, ENST00000587392, ENST00000588653, ENST00000589542, ENST00000590155, ENST00000901086, ENST00000901087, ENST00000901088, ENST00000901089, ENST00000901090, ENST00000901091, ENST00000933425

RefSeq mRNA: 4 — MANE Select: NM_001130031 NM_001130031, NM_001130032, NM_001300885, NM_017656

CCDS: CCDS12217, CCDS45956, CCDS74280

Canonical transcript exons

ENST00000453372 — 6 exons

Exon	Start	End
ENSE00002735427	9641807	9653881
ENSE00002868593	9675015	9675100
ENSE00003467472	9658009	9658135
ENSE00003517926	9659379	9659467
ENSE00003527776	9660720	9660874
ENSE00003784143	9656547	9656653

Expression profiles

Bgee: expression breadth ubiquitous, 280 present calls, max score 98.19.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 16.3067 / max 138.2236, expressed in 1748 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
179020	12.7684	1728
179019	3.1838	1451
179018	0.3545	179

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	98.19	gold quality
cervix squamous epithelium	UBERON:0006922	95.90	gold quality
nipple	UBERON:0002030	92.88	gold quality
amniotic fluid	UBERON:0000173	92.85	gold quality
pylorus	UBERON:0001166	92.14	gold quality
mucosa of paranasal sinus	UBERON:0005030	91.82	gold quality
seminal vesicle	UBERON:0000998	91.38	gold quality
tongue squamous epithelium	UBERON:0006919	91.06	gold quality
visceral pleura	UBERON:0002401	90.96	gold quality
mucosa of sigmoid colon	UBERON:0004993	90.94	gold quality
squamous epithelium	UBERON:0006914	90.44	gold quality
inferior vagus X ganglion	UBERON:0005363	89.90	gold quality
parietal pleura	UBERON:0002400	89.88	gold quality
oviduct epithelium	UBERON:0004804	89.86	gold quality
esophagus squamous epithelium	UBERON:0006920	89.83	gold quality
pleura	UBERON:0000977	89.69	gold quality
penis	UBERON:0000989	89.68	gold quality
corpus callosum	UBERON:0002336	89.62	gold quality
ventral tegmental area	UBERON:0002691	89.46	gold quality
medial globus pallidus	UBERON:0002477	89.37	gold quality
cardia of stomach	UBERON:0001162	89.36	gold quality
globus pallidus	UBERON:0001875	89.30	gold quality
renal medulla	UBERON:0000362	89.17	gold quality
oocyte	CL:0000023	89.00	gold quality
epithelium of esophagus	UBERON:0001976	88.74	gold quality
mammalian vulva	UBERON:0000997	88.61	gold quality
urethra	UBERON:0000057	88.60	gold quality
tendon of biceps brachii	UBERON:0008188	88.57	gold quality
colonic epithelium	UBERON:0000397	88.55	gold quality
colonic mucosa	UBERON:0000317	88.50	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.74

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

140 targeting ZNF562, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-1184	99.99	68.19	1458
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-4745-5P	99.98	65.95	1028
HSA-MIR-3148	99.97	75.06	6478

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	zfx	ENSDARG00000074453
danio_rerio		ENSDARG00000098424
mus_musculus	Zfy2	ENSMUSG00000000103
mus_musculus	Zfy1	ENSMUSG00000053211
rattus_norvegicus	Zfy1	ENSRNOG00000053042

Paralogs (38): ZFX (ENSG00000005889), ZBTB11 (ENSG00000066422), ZFAT (ENSG00000066827), ZFY (ENSG00000067646), ZNF586 (ENSG00000083828), IKZF5 (ENSG00000095574), ZNF419 (ENSG00000105136), ZNF549 (ENSG00000121406), ZSCAN20 (ENSG00000121903), ZNF304 (ENSG00000131845), PRDM15 (ENSG00000141956), ZNF660 (ENSG00000144792), ZNF711 (ENSG00000147180), ZNF773 (ENSG00000152439), ZNF256 (ENSG00000152454), ZNF837 (ENSG00000152475), ZNF691 (ENSG00000164011), ZNF610 (ENSG00000167554), E4F1 (ENSG00000167967), ZNF561 (ENSG00000171469), ZNF584 (ENSG00000171574), ZIK1 (ENSG00000171649), ZNF570 (ENSG00000171827), ZSCAN2 (ENSG00000176371), ZNF552 (ENSG00000178935), ZNF154 (ENSG00000179909), ZNF792 (ENSG00000180884), ZNF793 (ENSG00000188227), ZNF548 (ENSG00000188785), ZNF79 (ENSG00000196152), ZNF418 (ENSG00000196724), ZNF772 (ENSG00000197128), ZNF583 (ENSG00000198440), ZNF480 (ENSG00000198464), ZNF551 (ENSG00000204519), ZNF134 (ENSG00000213762), ZNF587B (ENSG00000269343), ZNF8 (ENSG00000278129)

Protein

Protein identifiers

Zinc finger protein 562 — Q6V9R5 (reviewed: Q6V9R5)

All UniProt accessions (7): A0A0G2JLJ0, Q6V9R5, K7EIE6, K7ELE4, K7EN01, K7ENE4, K7EQZ2

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in transcriptional regulation.

Subcellular location. Nucleus.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q6V9R5-1	1	yes
Q6V9R5-2	2

RefSeq proteins (4): NP_001123503, NP_001123504, NP_001287814, NP_060126 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001909	KRAB	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036051	KRAB_dom_sf	Homologous_superfamily
IPR036236	Znf_C2H2_sf	Homologous_superfamily

Pfam: PF00096, PF01352

UniProt features (18 total): zinc finger region 8, sequence variant 3, sequence conflict 3, splice variant 2, chain 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6V9R5-F1	60.39	0.16

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-212436	Generic Transcription Pathway

MSigDB gene sets: 50 (showing top): SHEDDEN_LUNG_CANCER_GOOD_SURVIVAL_A5, DODD_NASOPHARYNGEAL_CARCINOMA_UP, chr19p13, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, OISHI_CHOLANGIOMA_STEM_CELL_LIKE_UP, GOMF_TRANSCRIPTION_REGULATOR_ACTIVITY, ALKBH3_TARGET_GENES, DIDO1_TARGET_GENES, MIR8485, MIR548AJ_3P_MIR548X_3P, MIR548AE_3P_MIR548AQ_3P, MIR548AH_3P_MIR548AM_3P, MIR548J_3P, MIR6833_3P, MIR6873_3P

GO Biological Process (4): regulation of DNA-templated transcription (GO:0006355), regulation of transcription by RNA polymerase II (GO:0006357), regulation of macromolecule metabolic process (GO:0060255), regulation of primary metabolic process (GO:0080090)

GO Molecular Function (6): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), zinc ion binding (GO:0008270), DNA binding (GO:0003677), metal ion binding (GO:0046872), sequence-specific double-stranded DNA binding (GO:1990837)

GO Cellular Component (1): nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
RNA Polymerase II Transcription	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of metabolic process	2
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
regulation of DNA-templated transcription	1
transcription by RNA polymerase II	1
macromolecule metabolic process	1
primary metabolic process	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
regulation of transcription by RNA polymerase II	1
transition metal ion binding	1
nucleic acid binding	1
cation binding	1
double-stranded DNA binding	1
sequence-specific DNA binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

682 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF562	OR1E2	P47887	507
ZNF562	OR5H14	A6NHG9	506
ZNF562	MINDY4B	A8MYZ0	475
ZNF562	LRRC4B	Q9NT99	453
ZNF562	OR1E1	P30953	445
ZNF562	GAREM2	Q75VX8	434
ZNF562	DEFB113	Q30KQ7	417
ZNF562	INTS14	Q96SY0	400
ZNF562	SPAG11A	Q6PDA7	390
ZNF562	C8orf34	Q49A92	380
ZNF562	QSER1	Q2KHR3	374
ZNF562	PTPDC1	A2A3K4	371
ZNF562	ERI2	A8K979	370
ZNF562	CCDC47	Q96A33	355
ZNF562	EID2	Q8N6I1	348

IntAct

7 interactions, top by confidence:

A	B	Type	Score
ZNF562	ISLR	psi-mi:“MI:0914”(association)	0.530
TRIM28	ZNF320	psi-mi:“MI:0914”(association)	0.530
ZNF562	RRBP1	psi-mi:“MI:0915”(physical association)	0.400
TEX19	ZNF316	psi-mi:“MI:0914”(association)	0.350
ZNF562	MDM2	psi-mi:“MI:0914”(association)	0.350

BioGRID (36): SMARCAD1 (Affinity Capture-MS), CBX5 (Affinity Capture-MS), ZNF561 (Affinity Capture-MS), KBTBD6 (Affinity Capture-MS), PRAME (Affinity Capture-MS), ISLR (Affinity Capture-MS), TRIM39 (Affinity Capture-MS), KNG1 (Affinity Capture-MS), RNF187 (Affinity Capture-MS), TRIM41 (Affinity Capture-MS), ZNF561 (Affinity Capture-MS), TRIM39 (Affinity Capture-MS), SMARCAD1 (Affinity Capture-MS), ISLR (Affinity Capture-MS), RNF187 (Affinity Capture-MS)

ESM2 similar proteins: A0JPL0, A6NK53, E7ETH6, E9Q8G5, O14628, P21506, P51508, Q09FC8, Q13360, Q2M218, Q2M3X9, Q2VY69, Q3KQV3, Q3SY52, Q4R882, Q5HY98, Q5REN4, Q5RES8, Q68DI1, Q6NX49, Q6P280, Q6PG37, Q6V9R5, Q6ZMW2, Q7Z340, Q86XU0, Q8IYI8, Q8N587, Q8N720, Q8N859, Q8NB42, Q8NDW4, Q8NEK5, Q8WXB4, Q96MR9, Q96MU6, Q96NG8, Q96NJ3, Q96SR6, Q9BR84

Diamond homologs: A0JPL0, A1L1L7, A2A761, A2VDP4, A3KN36, A6QLU5, A6QPT6, A7MBI1, A8MT65, B2RXC5, E9PYI1, E9Q8G5, O75290, O94892, O95780, P10076, P17014, P17023, P17025, P17030, P17032, P17098, P51523, P51814, P52736, P52742, P58317, Q02975, Q06730, Q06732, Q08DG8, Q0VCB0, Q13360, Q14584, Q14587, Q14590, Q147U1, Q16587, Q29RZ4, Q2M218

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

66 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	54
Likely benign	6
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
545228	Single allele	Likely pathogenic

SpliceAI

920 predictions. Top by Δscore:

Variant	Effect	Δscore
19:9653877:GTCTG:G	acceptor_gain	0.9900
19:9653879:CTG:C	acceptor_gain	0.9900
19:9653880:TG:T	acceptor_gain	0.9900
19:9653882:C:CC	acceptor_gain	0.9900
19:9653885:A:AC	acceptor_gain	0.9900
19:9653885:A:C	acceptor_gain	0.9900
19:9653893:A:C	acceptor_gain	0.9900
19:9656654:C:CC	acceptor_gain	0.9900
19:9658002:CTCTT:C	donor_loss	0.9900
19:9658003:TCTTA:T	donor_loss	0.9900
19:9658004:CTTA:C	donor_loss	0.9900
19:9658005:TTACC:T	donor_loss	0.9900
19:9658006:TAC:T	donor_loss	0.9900
19:9658007:A:AC	donor_gain	0.9900
19:9658007:A:AG	donor_loss	0.9900
19:9658007:AC:A	donor_gain	0.9900
19:9658008:C:CC	donor_gain	0.9900
19:9658008:CC:C	donor_gain	0.9900
19:9658008:CCCA:C	donor_gain	0.9900
19:9658134:TCCT:T	acceptor_loss	0.9900
19:9659466:CC:C	acceptor_gain	0.9900
19:9659467:CC:C	acceptor_gain	0.9900
19:9653879:CTGC:C	acceptor_loss	0.9800
19:9653880:TGCTG:T	acceptor_loss	0.9800
19:9653881:GC:G	acceptor_loss	0.9800
19:9653882:C:CA	acceptor_loss	0.9800
19:9653883:T:A	acceptor_loss	0.9800
19:9653893:A:AC	acceptor_gain	0.9800
19:9658133:ATCCT:A	acceptor_gain	0.9800
19:9658136:C:CC	acceptor_gain	0.9800

AlphaMissense

2836 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:9653255:G:C	F325L	0.996
19:9653255:G:T	F325L	0.996
19:9653257:A:G	F325L	0.996
19:9653087:G:C	F381L	0.995
19:9653087:G:T	F381L	0.995
19:9653089:A:G	F381L	0.995
19:9653171:G:C	F353L	0.995
19:9653171:G:T	F353L	0.995
19:9653173:A:G	F353L	0.995
19:9653003:G:C	F409L	0.991
19:9653003:G:T	F409L	0.991
19:9653005:A:G	F409L	0.991
19:9658100:G:C	F50L	0.990
19:9658100:G:T	F50L	0.990
19:9658102:A:G	F50L	0.990
19:9653228:A:C	H334Q	0.988
19:9653228:A:T	H334Q	0.988
19:9658101:A:G	F50S	0.987
19:9653139:C:G	R364P	0.984
19:9653339:A:C	F297L	0.981
19:9653339:A:T	F297L	0.981
19:9653341:A:G	F297L	0.981
19:9658085:C:A	W55C	0.979
19:9658085:C:G	W55C	0.979
19:9653256:A:G	F325S	0.977
19:9653062:G:C	H390D	0.976
19:9653216:G:C	H338Q	0.976
19:9653216:G:T	H338Q	0.976
19:9658087:A:G	W55R	0.976
19:9658087:A:T	W55R	0.976

dbSNP variants (sampled 300 via entrez): RS1000196481 (19:9669894 T>A), RS1000224318 (19:9669732 GCGCACACACA>G), RS1000248262 (19:9646002 T>C,G), RS1000308117 (19:9641410 C>T), RS1000595317 (19:9649837 T>G), RS1000597178 (19:9665395 T>C), RS1000639137 (19:9642311 T>C), RS1000672349 (19:9675142 A>G), RS1000691418 (19:9642140 C>G,T), RS1000723497 (19:9666437 C>T), RS1000994401 (19:9655594 A>G), RS1000998922 (19:9650954 C>A), RS1001032351 (19:9645879 C>A,T), RS1001109804 (19:9660499 G>A,C), RS1001147089 (19:9674976 C>T)

Disease associations

OMIM: gene `` | disease phenotypes: MIM:209850

GenCC curated gene-disease

Mondo (1): autism (MONDO:0005260)

Orphanet (0):

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000717	Autism

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D001321	Autistic Disorder	F03.625.164.113.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects expression, affects cotreatment, increases abundance, increases expression	3
Ozone	affects cotreatment, decreases expression, increases oxidation, increases abundance, affects expression	3
methacrylaldehyde	increases abundance, affects cotreatment, decreases expression, increases oxidation	2
Acrolein	affects cotreatment, decreases expression, increases oxidation, increases abundance	2
Air Pollutants	decreases expression, increases abundance, increases oxidation, affects expression, affects cotreatment	2
Arsenic	affects methylation, affects cotreatment, increases abundance, increases expression	2
TAK-243	increases sumoylation	1
testosterone enanthate	affects expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, decreases expression, increases oxidation, increases abundance	1
bisphenol A	affects cotreatment, decreases expression	1
trichostatin A	affects expression	1
cobaltous chloride	increases expression	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
di-n-butylphosphoric acid	affects expression	1
belinostat	increases expression	1
ICG 001	increases expression	1
jinfukang	affects cotreatment, decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Temozolomide	increases expression	1
Sunitinib	decreases expression	1
Atrazine	decreases expression	1
Cisplatin	affects cotreatment, decreases expression	1
Dexamethasone	affects cotreatment, decreases expression	1
Doxorubicin	decreases expression	1
Indomethacin	affects cotreatment, decreases expression	1
Manganese	affects cotreatment, increases abundance, increases expression	1
Naled	affects expression	1
Plant Extracts	affects cotreatment, increases expression	1
Silver	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00211796	PHASE4	COMPLETED	Divalproex Sodium ER in Adult Autism
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT00409747	PHASE4	COMPLETED	Minocycline to Treat Childhood Regressive Autism
NCT00576732	PHASE4	COMPLETED	A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder
NCT00844753	PHASE4	COMPLETED	Atomoxetine, Placebo and Parent Management Training in Autism
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01098383	PHASE4	UNKNOWN	Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02069977	PHASE4	UNKNOWN	Study to Evaluate the Efficacy and Safety of Aripiprazole
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02199925	PHASE4	UNKNOWN	An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02255565	PHASE4	COMPLETED	Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT00036231	PHASE3	TERMINATED	Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction
NCT00036244	PHASE3	COMPLETED	Synthetic Human Secretin in Children With Autism
NCT00065884	PHASE3	UNKNOWN	Valproate Response in Aggressive Autistic Adolescents
NCT00065962	PHASE3	COMPLETED	Secretin for the Treatment of Autism
NCT00252603	PHASE3	COMPLETED	Galantamine Versus Placebo in Childhood Autism
NCT00346736	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00352248	PHASE3	COMPLETED	Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autistic Spectrum Disorder
NCT00352352	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00355329	PHASE3	COMPLETED	Randomized Control Trial of Using Tongue Acupuncture in Autistic Spectrum Disorder Using PET Scan for Clinical Correlation
NCT00498173	PHASE3	COMPLETED	Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism
NCT00541346	PHASE3	COMPLETED	A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms